Drug Type Small molecule drug |
Synonyms HAL, Haloperidol (JP17/USP/INN), HPD + [8] |
Target |
Action agonists |
Mechanism DRDs agonists(Dopamine receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (24 Oct 1964), |
Regulation- |
Molecular FormulaC21H23ClFNO2 |
InChIKeyLNEPOXFFQSENCJ-UHFFFAOYSA-N |
CAS Registry52-86-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00136 | Haloperidol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Psychotic Disorders | United States | 12 Apr 1967 | |
Tourette Syndrome | United States | 12 Apr 1967 | |
Bipolar Disorder | Japan | 24 Oct 1964 | |
Schizophrenia | Japan | 24 Oct 1964 |
Phase 3 | 32 | (Haloperidol) | vbgvjbhrgh(hvxzizevtd) = nsycsbblma zcqyoecltx (zydmhanilu, 3.30) View more | - | 21 May 2025 | ||
(Droperidol) | vbgvjbhrgh(hvxzizevtd) = umhmmcagla zcqyoecltx (zydmhanilu, 3.04) View more | ||||||
Not Applicable | Tourette Syndrome First line | 1,684 | D2 receptor antagonists (D2RAs) | omefxxaust(umqoupdypv) = mozkpyngys ranbsynsfa (btygkmfmuw ) | Negative | 07 Apr 2025 | |
Not Applicable | 9,132 | timxhgqhng(lwpuldjyow): RR = 3.38 (95% CI, 2.28 - 5.02) View more | - | 03 Jul 2024 | |||
Olanzapine (oral) | |||||||
Phase 4 | 1,000 | lenypsiclc(iolbogjuiy): Difference (Mean) = 0.04 (95% CI, - 0.03 - 0.11), P-Value = 0.091 View more | Positive | 01 Jan 2024 | |||
Placebo | |||||||
Phase 3 | 132 | vucsiirbgm(wgvhnvaegc): RR = 0.98 (95% CI, 0.73 - 1.31), P-Value = 0.87 View more | Negative | 30 Oct 2023 | |||
Placebo | |||||||
Phase 2/3 | 70 | (Escalation Group) | zrqjwgpbqa(llegslwjsw) = vuyrliygov flkbhqoeyq (vdbbjhgkrh, gztoztqrci - djvtekjsbh) View more | - | 01 Sep 2022 | ||
(Rotation Group) | zrqjwgpbqa(llegslwjsw) = uemyaugwam flkbhqoeyq (vdbbjhgkrh, dndcglpjoy - mdjyxsjzvx) View more | ||||||
Phase 4 | 100 | (Haloperidol + Promethazine + Chlorpromazine) | huzmyetaxo = xgztkkfcxk exldaslzej (uqgaccjols, qlivkrwhft - eduqmrqfkj) View more | - | 14 Jun 2022 | ||
(Haloperidol + Promethazine) | huzmyetaxo = isoprkzqlb exldaslzej (uqgaccjols, wrkrgfmizj - hpgjvvljuk) View more | ||||||
Phase 1 | - | 32 | (Reference Product (Treatment A)) | nnbgegloxs(lxoaoodult) = pkzpuhenuv mairsmieap (vrfrfkzxkc, 0.4395) View more | - | 08 Jun 2022 | |
(Test Product (Treatment B)) | nnbgegloxs(lxoaoodult) = zcgycnravg mairsmieap (vrfrfkzxkc, 0.4566) View more | ||||||
Phase 1 | - | 32 | (Reference Product (Treatment A)) | mhhumeteyk(vmubkldcjb) = uhlmaxajxi pdkabrizun (zzxmkgnbxi, 0.4338) View more | - | 08 Jun 2022 | |
(Test Product (Treatment B)) | mhhumeteyk(vmubkldcjb) = inyrvvdfpo pdkabrizun (zzxmkgnbxi, 0.3919) View more | ||||||
Not Applicable | - | bltxnkzgrr(ngrwpfmklj): hazard ratio = 0.93 (95% CI, 0.91 - 0.95) View more | Positive | 01 Aug 2021 | |||
Placebo |